Clinical Trial Update: Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating pembrolizumab with nab-paclitaxel followed by pembrolizumab with epirubicin/cyclophosphamide in triple-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Institut fuer Frauengesundheit | Conditions: Malignant Neoplasm of Breast | Phase 2 | Status: COMPLETED